SGB-9768 (C3 siRNA) Clinical Data to be Reported at ASN Kidney Week 2025

BOSTON, SHANGHAI, and SUZHOU – October 25, 2025, SanegeneBio, a clinical-stage biotechnology focused on developing best-in-class RNAi medicines for obesity, cardiometabolic, and autoimmune diseases, today announced its participation at the American Society of Nephrology (ASN) Kidney Week 2025, November 5-9 in Houston, TX, USA. Safety and pharmacodynamic data from two Phase 1 studies of SGB-9768, an investigational RNAi therapeutic targeting C3, conducted at New Zealand Clinical Research and Huashan Hospital of Fudan University in China, will be shared in a poster presentation.

IgAN (IgA Nephropathy) is the most common primary glomerular disease in China, with an estimated 4 million patients, predominantly affecting young and middle-aged adults. IgAN is the leading cause of end-stage renal disease (ESRD) in this demographic in China. Studies show that approximately 50% of IgAN patients with persistent proteinuria progress to ESRD within 10-20 years after diagnosis, requiring dialysis or kidney transplantation. C3G (C3 Glomerulopathy) is a rare kidney disease with a global incidence of 1-2 per million people per year, primarily affecting young adults. Approximately 50% of patients progress to ESRD within 10 years, requiring dialysis or kidney transplantation; post-transplantation, the disease recurs in 50%-70% of patients, making its clinical management extremely challenging.

Despite their differing incidence rates, both IgAN and C3G are closely linked to complement activation. They share the severe challenges of rapid progression and limited treatment options, significantly threatening patient survival and quality of life. SGB-9768 is designed to inhibit complement activation, offering a potential new treatment option for complement-mediated kidney diseases. Phase I data indicate that SGB-9768 has demonstrated a favorable safety profile and greater durability. Furthermore, it demonstrated robust, dose-dependent, and sustained reduction in C3 levels, showing superior C3 gene silencing potency and durability compared to prior C3 RNAi candidates.

Kidney Week, organized by the American Society of Nephrology (ASN), is the world's premier nephrology meeting. It attracts over 12,000 nephrology professionals from across the globe, provides a dynamic platform for participants to exchange knowledge, learn the latest scientific and medical advances, and engage in thought-provoking discussions with leading experts. The conference serves as a vital platform dedicated to driving innovation in the diagnosis and treatment of kidney disease worldwide.

ASN Kidney Week 2025 | (November 5-9)

[Title] Safety and Pharmacodynamics of SGB-9768, a siRNA Targeting Complement C3 in Healthy Volunteers
[Speaker] Dr Nicholas Cross, Principal Investigator of SGB-9768, New Zealand Clinical Research
[Time Slot] November 8, 10:00 AM – 12:00 PM
[Abstract ID]
[Location] Houston, TX

About SGB-9768

SGB-9768 is a GalNAc-conjugated experimental RNAi-based medicine designed to silence C3 mRNA in hepatocytes, thereby inhibiting complement activation. It is a potential treatment for various complement-mediated kidney diseases, including IgAN, C3G, and IC-MPGN. It has demonstrated potent, sustained reduction in C3 levels following a single subcutaneous dose, with the potential for infrequent dosing and long-term efficacy. With a favorable safety profile and greater durability than comparator molecules, SGB-9768 may become a best-in-class RNAi therapeutic for complement-mediated diseases.

About SanegeneBio

SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021, SanegeneBio is led by a team of RNAi pioneers with unrivaled experience in this Nobel Prize-winning technology. With R&D operations in Boston, Shanghai and Suzhou, our vision clear – RNAi technology will power blockbuster medicines in diverse therapeutic areas, improving the quality and longevity of life for countless patients in the coming years. Our fast-growing pipeline includes experimental medicines for autoimmune nephropathies, obesity, and cardiometabolic indications. SanegeneBio has initiated clinical trials for several experimental medicines, and is committed to developing potential best-in-class and first-in-class therapeutics which leverage our industry-leading and differentiated LEAD™ tissue-selective RNAi delivery technology. For more information, please visit: www.sanegenebio.com and engage with us on LinkedIn.

Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. Any statements in this release other than statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "could," "potential," "is/are likely to," "will," "plan," "intend," "aim," "expect," "anticipate," "believe," "hope," "estimate," "project," "forecast," "continue," "target," and similar expressions (or the negative of these terms) are intended to identify forward-looking statements. In addition, statements that refer to future results, trends in our business, expectations for our product pipeline or product candidates, or other characterizations of future events or circumstances are forward-looking statements.

These forward-looking statements are based on our current expectations and assumptions as of the date of this news release and speak only as of such date. They are not guarantees of future performance, and actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of risks and uncertainties, many of which are beyond our control. These risks and uncertainties include, without limitation: risks in research and development and clinical trials; regulatory review, requirements, and timing; trial initiation, site activation, enrollment, and operational execution (including performance by third parties); manufacturing, supply, and quality risks; the impact of competition and new technologies; future market conditions; macroeconomic, political, legal, and social conditions; and our ability to obtain and maintain sufficient funding and other resources. Readers are cautioned not to place undue reliance on these forward-looking statements. We assume no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise, except as required by applicable law.

Medical Information
This press release is provided for informational purposes only and is intended to share scientific and disease-related information. It is not intended as advertising or commercial promotion of any product and does not constitute medical advice, a diagnosis, or a recommendation for any treatment or use of any product. For questions about medical conditions or treatment, please seek advice from a healthcare professional.